Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement....
+See More2017-12-17 11:41:00 Sunday ET
Warren Buffett points out that it is important to invest in oneself. Learning about oneself empowers him or her to lead a meaningful life. This valuable inv
2020-02-02 11:32:00 Sunday ET
Our fintech finbuzz analytic report shines fresh light on the current global economic outlook. As of Winter-Spring 2020, the analytical report delves into t
2023-12-10 09:23:00 Sunday ET
U.S. federalism and domestic institutional arrangements A given country is federal when both of its national and sub-national governments exercise separa
2019-12-28 09:36:00 Saturday ET
Global debt surges to $250 trillion in the fiscal year 2019. The International Institute of Finance analytic report shows that both China and the U.S. accou
2024-01-31 14:33:00 Wednesday ET
The new world order of trade helps accomplish non-economic policy goals such as national security and technological dominance. To the extent that freer
2017-08-07 09:39:00 Monday ET
Global financial markets suffer as President Trump promises *fire and fury* in response to the recent report that North Korea has successfully miniaturized